Health
Heterologous AstraZeneca and Pfizer vaccines induce strong immune response and T cell reactivity against multiple SARS-CoV-2 variants – News-Medical.Net
Researchers from Germany recently analyzed a cohort of 26 individuals in the age range of 25 to 46 (median 30.5) years who had received a ChAdOx1 nCoV-19 prime…
The first person to receive a coronavirus disease 2019 (COVID-19) vaccine outside a clinical trial did so within 250 days of the first case of COVID-19 being reported to the World Health Organization (WHO) in late 2019. Mass vaccination efforts are now a key strategy for controlling the pandemic. Several vaccines have been approved, including the mRNA-based BNT162b2 (Comirnaty, BioNTech/Pfizer) and the adenovirus-based ChAdOx1 nCoV-19 (Vaxzevria, AstraZeneca).
Both these vaccines induce humoral…
-
General19 hours agoByford rail extension opening marks final stage of Perth Metronet
-
General21 hours agoMango the muster cat draws attention to western Queensland’s ongoing recovery
-
Business23 hours agoWhat $10,000 invested in the iShares S&P 500 IVV ETF could be in 10 years
-
General12 hours agoAustralia’s Diamonds defeat South Africa’s Proteas 65-42 in third netball Test